

Charity registration number 1046278 (England and Wales)

Company registration number 03050367

FRIENDS OF ROSIE

CHILDRENS CANCER RESEARCH FUND

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	Ms A T Mogg Ms F M S Goodey CBE DL Ms L A Dowdall Mr M Vara Mr R C Rea Ms K London Mrs J Crosby Ms C Nuttall Mr J Hickman PhD A Dykes	(Appointed 1 February 2025) (Appointed 1 July 2025)
Secretary	Ms A T Mogg	
Honorary President	Lisa Larkin MBE	
Charity number	1046278	
Company number	03050367	
Registered office	86 Deansgate Manchester	
Independent examiner	David Kay FCA Barlow Andrews LLP Carlyle House 78 Chorley New Road Bolton	
Bankers	Royal Bank of Scotland Drummond House 1 Redheughs Avenue Edinburgh	
Solicitors	Slater Heelis Limited 86 Deansgate Manchester	

FRIENDS OF ROSIE CHILDRENS CANCER RESEARCH FUND CONTENTS

	Page
Trustees' report	1 - 4
Statement of trustees' responsibilities	5
Independent examiner's report	6
Statement of financial activities	7
Balance sheet	8
Notes to the financial statements	9 - 13

FRIENDS OF ROSIE CHILDRENS CANCER RESEARCH FUND TRUSTEES' REPORT (INCLUDING DIRECTOR'S REPORT) FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their annual report and financial statements for the year ended 31 March 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

'Friends of Rosie, Children's Cancer Research Fund', was established with one key objective, to fund early-stage research with the potential of finding kinder, more effective treatment and possible cures for children with cancer. The founders were Lisa and Patrick Larkin, parents of a little girl called Rosie who lost her life at the age of 5. There is still no cure for the cancer which killed Rosie. Progress has been made in many areas but there are still too many treatments designed for adults which have devastating side effects on children and still conditions for which there is no cure. Getting that message across to the wider public requires effective communication and communications have undergone radical change since Friends of Rosie was created. This year the Charity undertook a professionally-led rebranding exercise and, with the full support of Rosie's parents, decided to amend its name. 'Friends of Rosie' will henceforth be known simply as 'Children's Cancer Research Fund' (C.C.R.F.).

Cancer is the biggest killer of children under 14. Yet it continues to receive a small fraction of the support which goes into combatting adult cancer whether from public funds, charity or the pharmaceutical companies. The Charity was created at the request of scientists and clinicians who find attracting funds for the earliest stages of research extremely challenging. It is now an accredited member of the Association of Medical Research Charities (AMRC).

At the core of the Charity from the outset is a highly distinguished International Scientific Advisory Board (SAB). The current chair, Dr Mark Gaze, has been a Consultant Clinical Oncologist at Great Ormond Street Hospital (GOSH) since 1993. He is also a consultant at University College Hospital, Chairman of the Children's Cancer and Leukaemia Group, lead for radiotherapy in clinical trials run by the European Paediatric Soft Tissue Sarcoma Group (EpSSG) and the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN). Dr Gaze will retire as Chair of the SAB in September 2025. The CCRF would like to thank him and acknowledge his invaluable work together with the work and support of three other SAB colleagues whose terms of office also end in September. Under Dr Gaze's leadership several important new studies have been completed and a very successful International Symposium held to discuss how to make molecular radiotherapy work better for children with neuroblastoma. A detailed report from the symposium has been published in the high-impact publication, *American Journal of Nuclear Medicine*.

The SAB is currently designing the next in the Charity's series of two-day International Symposia held bi-annually in Manchester. The theme for 2026 will be the treatment of childhood leukaemia.

Trustees have authorised a new call for Grant proposals, applications for which are due by the 31st of October 2025.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake and firmly believe that the charity continues to meet the requirement to provide public benefit.

FRIENDS OF ROSIE CHILDRENS CANCER RESEARCH FUND TRUSTEES' REPORT (INCLUDING DIRECTOR'S REPORT) (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Achievements and performance

Significant activities and achievements against objectives

Proton Beam Therapy Project

At the start of January, Dr Amy Chadwick and Dr Emma Biglin began the second year of a research project funded by the CCRF to explore the potential of proton beam therapy in treating paediatric cancers. Over the first year of this study, they made significant strides in their research, focusing on how cells respond to this advanced form of radiotherapy under low oxygen conditions and in combination with different drugs. This project is being carried out at The Christie Hospital in Manchester. Proton beam therapy (PBT) uses high energy proton beams in place of conventional X-rays. The unique physical properties of protons means that protons stop at a precise depth in tissue, with no radiation dose delivered beyond. Lead researcher, Dr Amy Chadwick says the project is very ambitious. "Our goal is to increase the effectiveness of proton beam therapy, with potential to decrease the dose of radiation to reduce the side effects for children with cancer. In their first year, the team carried out high-throughput drug screening on 355 compounds in combination with proton beam therapy under hypoxic conditions. This leading-edge work has yielded promising results in year one, and we believe they are the only team in the world with this capability, making this research particularly significant.

During their second year of research, Amy and Emma aim to validate the drug combinations they found to be effective. They will expand their research to different models and further understand how these combinations work. Dr Chadwick says: "We're already having discussions with other collaborators to look at the potential to translate our findings into real-world treatments that could benefit children with cancer. By the end of our second year, we aim to publish our work and secure larger grants to continue this pioneering research."

Blood-tests for neuroblastoma clinical trials to guide next-generation cancer treatments

In 2021, we were delighted to collaborate with Neuroblastoma UK on a research grant of £469,093, awarded to an international team of leading clinician-scientists to explore how blood tests (biomarker testing) could be used in clinical trials to improve outcomes for children with neuroblastoma.

Professor Louis Chesler's research grant was co-funded by Neuroblastoma UK (£454,093) and Children's Cancer Research Fund (£15,000) as part of Neuroblastoma UK's 2021 Grant Round.

Thanks to the grant provided by Neuroblastoma UK and Children's Cancer Research Fund, scientists have been able to evaluate the accuracy and reliability of the blood-tests, making them ready for use in clinical trials when they are appropriately integrated into a clinical workflow.

The legacy of this research will also contribute to further collaboration across the UK and Europe. Helping to bring together field leaders and creating a more standardised way of testing cancerous DNA across Europe and the UK. This will support future collaboration, accelerating progress for the next generation of clinical trials.

Blood-tests are now being implemented in clinical trials including the SIOPEN pragmatic clinical trial to 'Monitor Neuroblastoma Relapse with Liquid Biopsy Sensitive Analysis' (MONALISA). This promising clinical trial hopes to improve early detection of relapse, overall survival rates, outcomes for patients and changes in care strategy.

Partnerships

In the past year the Charity has part funded individual research projects as well as the International Symposium by inviting collaboration from other smaller charities or being willing to collaborate with another funder. The Charity is encouraging smaller organisations, who do not have access to the same level of scientific and clinical advice built up by CCRF (aka Friends of Rosie) to join with us to put some of their money into research projects which they can be confident have been fully vetted and appraised by experts. CCRF makes no charge for this and freely shares any resulting publicity with co-funders.

FRIENDS OF ROSIE CHILDRENS CANCER RESEARCH FUND TRUSTEES' REPORT (INCLUDING DIRECTOR'S REPORT) (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Challenge events

Led by Trustee Katrina London and strongly supported by several other Trustees, CCRF (aka) Friends of Rosie has begun fielding teams in Challenge Events across the UK and in Europe. Supporters can run, cycle or even bounce their way to raising funds to support vital research into childhood cancers. Our latest team is the crew of a super Yacht in the Mediterranean!

Ward 86 Christmas Party

A Christmas party for the children and families of the Manchester Children's Hospital cancer wards is not strictly within the Charity's remit. But when it transpired that the annual Christmas party for these very vulnerable children had lapsed when the original organisers retired, Friends of Rosie (CCRF) Trustees agreed unanimously that the charity should try to revive it. Three other small charities quickly answered the call and together a Christmas Party was held in December 2023 hosted by Bruntwood SciTech opposite the Manchester Children's Hospital. Sadly in 2024 too many of our key organisers were unable to help but we are delighted to announce that plans for a Ward 84 party this Christmas, 2025, are well advanced and generously sponsored. Our thanks in particular to Bruntwood SciTech who are once again providing the facilities.

CCRF is also delighted to announce that Bruntwood SciTech has adopted the charity as an official sponsor and corporate supporter and will be working together with us on an exciting range of new fundraising opportunities in the coming year.

Children's Cancer Research Fund, (aka Friends of Rosie)

The Charity would like to thank all its hard-working Trustees, volunteers and many supporters and sponsors, especially the PJ Livesey Group whose owners and staff have been fund raising for the Charity from the start and continue to be active and enthusiastic supporters.

The Charity continues to be volunteer-led, ensuring that ninety five percent of funds raised go directly into research or related activity, enabling children with cancer to thrive and survive.

Financial review

In the current financial year total income decreased from £79,712 to £70,316. Donations and legacies remain the principal source of our funding. Expenditure decreased from £119,236 to £50,834, with the loss of the grants awarded in the previous year. Funds, all of which are unrestricted, increased by £19,482 and at the balance sheet date stood at £100,480, which the trustees believe is sufficient to meet the charity's needs and statutory obligations for the foreseeable future.

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level at least equivalent to between three and six months' running costs. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. There has been an increase in reserves this year and the target level of free reserves has been maintained throughout the year, the charity's level of free reserves being £100,480 (2024 - £80,998) at the financial year end.

Major risks

The trustees have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

Plans for future periods

In addition to some specific plans outlined in the various sections of the foregoing review of achievements and performance, the charity will continue to raise funds for the research and treatment of cancer in children.

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
TRUSTEES' REPORT (INCLUDING DIRECTOR'S REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

Structure, governance and management

The charity is a registered charity, number 1046278 and is governed by its Memorandum and Articles of Association dated 27 April 1995. The company (registered number 03050367) has no share capital and is limited by guarantee. None of the trustees has any beneficial interest in the company. Anyone over the age of 18 can become a member of the company. Members agree to contribute £1 in the event of winding up.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Ms A T Mogg

Ms F M S Goodey CBE DL

Ms L A Dowdall

Mr M Vara

Mr R C Rea

Ms K London

Mrs J Crosby

Ms C Nuttall

Mr J Hickman PhD

(Appointed 1 February 2025)

A Dykes

(Appointed 1 July 2025)

Recruitment and appointment of trustees

Trustees are appointed based on their expertise from recommendations of the existing trustees.

CCRF is delighted to welcome two new Trustees:

Antonia Dykes, has joined as a new parent Trustee. Antonia has a degree in fine art and is passionate about art education for young people, having worked in schools in the UK and on the island of St. Helena. She is mum to 3 daughters, one of whom was diagnosed with rhabdomyosarcoma aged 2 in January 2017. After more than a year of various treatments she relapsed in September 2018 and finally finished all treatment in November 2019. Antonia's family travelled to Germany twice for her daughter to have proton beam therapy which wasn't available in the UK at the time. She brings with her a unique perspective and invaluable insight as a parent with lived experience of childhood cancer.

Professor John Hickman DSc, former Professor of Molecular Pharmacology at the University of Manchester; lead pharmacologist for the discovery of the drug Temozolomide, used to treat brain cancers; director of cancer drug discovery at Servier and coordinator of a European Union Innovative Medicines Initiative (IMI) consortium. Prof. Hickman is also a past Charman of the CCRF Scientific Advisory Board.

The trustees' report was approved by the Board of Trustees.

Mr R C Rea

Trustee

28 October 2025

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 MARCH 2025**

The trustees, who are also the directors of FRIENDS OF ROSIE for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF FRIENDS OF ROSIE**

I report to the trustees on my examination of the financial statements of FRIENDS OF ROSIE (the charity) for the year ended 31 March 2025.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law), you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006.

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the Companies Act 2006 and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011. In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the Charities Act 2011.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the Companies Act 2006.
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the Companies Act 2006 other than any requirement that the financial statements give a true and fair view, which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



David Kay FCA
Barlow Andrews LLP
Chartered Accountants
Carlyle House
78 Chorley New Road
Bolton

Dated: 28 October 2025

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2025**

	Notes	Unrestricted funds 2025 £	Unrestricted funds 2024 £
<u>Income from:</u>			
Donations and legacies	2	69,421	78,824
Investments		895	888
Total income		<u>70,316</u>	<u>79,712</u>
<u>Expenditure on:</u>			
Charitable activities	3	50,834	119,236
Net income/(expenditure) for the year/ Net movement in funds		19,482	(39,524)
Fund balances at 1 April 2024		<u>80,998</u>	<u>120,522</u>
Fund balances at 31 March 2025		<u><u>100,480</u></u>	<u><u>80,998</u></u>

The statement of financial activities includes all gains and losses recognised in the year.

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
BALANCE SHEET
AS AT 31 MARCH 2025**

	Notes	2025 £	£	2024 £	£
Current assets					
Cash at bank and in hand		176,371		171,901	
Creditors: amounts falling due within one year	10	<u>(75,891)</u>		<u>(90,903)</u>	
Net current assets			<u>100,480</u>		<u>80,998</u>
The funds of the charity					
Unrestricted funds	11		<u>100,480</u>		<u>80,998</u>
			<u>100,480</u>		<u>80,998</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2025.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 28 October 2025

Mr R C Rea
Trustee

Company registration number 03050367 (England and Wales)

FRIENDS OF ROSIE CHILDRENS CANCER RESEARCH FUND NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

Charity information

FRIENDS OF ROSIE is a private company limited by guarantee incorporated in England and Wales. The registered office is 86 Deansgate, Manchester.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include office costs, finance, personnel, payroll and governance costs which support the charity's activities.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

2 Donations and legacies

	Unrestricted funds	Unrestricted funds
	2025	2024
	£	£
Donations and gifts	69,421	78,824
	<u>69,421</u>	<u>78,824</u>

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

3 Expenditure on charitable activities

	2025	2024
	£	£
Marketing and communications	22,125	25,926
Conference costs	24,671	-
Sundry expenses	1,529	2,273
Bank charges	64	77
Insurance	655	616
	<u>49,044</u>	<u>28,892</u>
Grant funding of activities (see note 4)	-	88,857
Share of support and governance costs (see note 5)		
Governance	1,790	1,487
	<u>50,834</u>	<u>119,236</u>
Analysis by fund		
Unrestricted funds	<u>50,834</u>	<u>119,236</u>

4 Grants payable

	2025	2024
	£	£
The University of Manchester	-	18,857
Dr Chadwick Research	-	70,000
	<u>-</u>	<u>88,857</u>

5 Support costs

	Governance costs	2025	2024	Basis of allocation
	£	£	£	
Independent examination fees	1,790	1,790	1,487	Governance
	<u>1,790</u>	<u>1,790</u>	<u>1,487</u>	

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

6	Net movement in funds	2025	2024
		£	£

The net movement in funds is stated after charging/(crediting):

Fees payable for the independent examination of the charity's financial statements	1,790	1,487
	<u> </u>	<u> </u>

7 Trustees

None of the trustees and directors (or any persons connected with them) received any remuneration or benefits from the charity during the year.

No trustee expenses were incurred during the current or previous year.

8 Employees

There were no employees during the current or previous year.

9 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

10 Creditors: amounts falling due within one year

	2025	2024
	£	£
Grants payable	70,000	87,366
Accruals and deferred income	5,891	3,537
	<u> </u>	<u> </u>
	<u>75,891</u>	<u>90,903</u>

11 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 April 2024	Incoming resources	Resources expended	At 31 March 2025
	£	£	£	£
General funds	80,998	70,316	(50,834)	100,480
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 April 2023	Incoming resources	Resources expended	At 31 March 2024
	£	£	£	£
General funds	120,522	79,712	(119,236)	80,998
	<u> </u>	<u> </u>	<u> </u>	<u> </u>

**FRIENDS OF ROSIE
CHILDRENS CANCER RESEARCH FUND
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
*FOR THE YEAR ENDED 31 MARCH 2025***

12 Related party transactions

There were no disclosable related party transactions during the year (2024 - none).